

REMARKS/ARGUMENTS

The Pending Claims

Claims 25, 27, 32-34, 66-68, and 70-72 are pending and are directed to a mutant *ras* peptide (claim 72), a mutant *ras* peptide-carrier molecule conjugate (claims 25, 66, and 67), an immunogen comprising the mutant *ras* peptide (claim 27), and a pharmaceutical composition comprising the mutant *ras* peptide (claims 32-34, 68, 70, and 71).

Amendment to the Specification

Applicants request entry of the sequence listing submitted herewith. No new matter is added by way of the sequence listing submitted herewith.

Amendments to the Claims

Claims 11-15 have been canceled. Applicants reserve the right to pursue the subject matter of the canceled claims in a continuation, continuation-in-part, divisional application, or other application. Cancellation of any subject matter should not be construed as abandonment of that subject matter.

No new matter has been added by way of these amendments to the claims.

Summary of the Office Action

The Office indicates that claims 25, 27, 32-34, 66-68, and 70-72 are allowed.

The Office objects to claims 12-15 for allegedly failing to comply with the Sequence Rules.

The Office rejects claims 11-15 under 35 U.S.C. § 112, first paragraph, for allegedly lacking written description.

Reconsideration of the objections and rejections is hereby requested.

Discussion of the Claim Objections

The Office indicates that the sequence listing submitted May 8, 2008, was defective because it was submitted in pdf format. Therefore, the Office objects to claims 12-15.

Applicants herein submit another copy of the sequence listing originally submitted on May 8, 2008, wherein the sequence listing is an ASCII text file. Additionally, as noted above, claims 12-15 have been canceled.

Applicants believe the claim objections are moot in view of the amendments to the claims and the resubmission of the sequence listing. Therefore, Applicants request that the claim objections be withdrawn.

Discussion of the Written Description Rejection


The Office contends that the specification fails to describe a genus of truncated peptides as recited in claims 11-15. Although Applicants disagree with the Office's contention, in an effort to advance prosecution, claims 11-15 have been canceled.

Applicants believe that the written description rejection is moot in view of the amendments to the claims. Therefore, Applicants request that the written description rejection be withdrawn.

Conclusion

Applicants respectfully submit that the patent application is in condition for allowance. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned agent.

Respectfully submitted,

A handwritten signature in cursive script, reading "Rachel J. Mejdrich".

Rachel J. Mejdrich, Reg. No. 53,477
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson Avenue
Chicago, Illinois 60601-6731
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: June 3, 2009